BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th
September 29, 2021 12:16 ET
|
BioCorRx Inc
ANAHEIM, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Files Patent Application with USPTO for Naltrexone Implant
September 22, 2021 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
September 08, 2021 07:00 ET
|
BioCorRx Inc
SAN DIEGO, CA, and ANAHEIM, CA, Sept. 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO)...
BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
September 01, 2021 08:30 ET
|
BioCorRx Inc
On track to commence the first-in-human clinical trial for BICX104 ANAHEIM, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
BioCorRx Provides Business Update for the Second Quarter of 2021
August 16, 2021 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Aug. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Welcomes Four Experts to Expanded Scientific Advisory Board
June 22, 2021 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, June 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of...
BioCorRx Provides Business Update for the First Quarter of 2021
May 18, 2021 09:05 ET
|
BioCorRx Inc
ANAHEIM, CA, May 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of...
BioCorRx Receives FDA Clearance of Investigational New Drug (IND) Application for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
May 10, 2021 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, May 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of...
BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone
April 13, 2021 08:00 ET
|
BioCorRx Inc
ANAHEIM, CA, April 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a developer and provider of advanced solutions in the treatment of...
BioCorRx Provides 2020 Year-End Business Update
April 01, 2021 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, April 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...